Loading...
EAR logo

Eargo, Inc.Informe acción NasdaqGS:EAR

Capitalización bursátil US$53.4m
Precio de las acciones
n/a
Mi valor justo
No disponible
1Y-64.3%
7D-2.7%
Valor de la cartera
​
Ver

Eargo, Inc.

Informe acción NasdaqGS:EAR

Capitalización de mercado: US$53.4m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Eargo (EAR) Resumen de Acciones

Eargo, Inc. es una empresa de dispositivos médicos dedicada a mejorar la calidad de vida de las personas con pérdida auditiva en Estados Unidos. Saber más

Análisis fundamental de EAR
Puntuación del snowflake
Valoración2/6
Crecimiento futuro0/6
Rendimiento pasado0/6
Salud financiera4/6
Dividendos0/6

Análisis de riesgos

Los beneficios han disminuido un 35.8% al año en los últimos 5 años

Tiene menos de 1 año de cash runway

No tiene una capitalización de mercado significativa ($53M)


EAR Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Competidores de Eargo, Inc.

Historial de precios y rendimiento

Resumen de las cotizaciones máximas, mínimas y variaciones del Eargo
Precios históricos de las acciones
Precio actual de la acciónUS$2.57
Máximo en las últimas 52 semanasUS$7.52
Mínimo de 52 semanasUS$1.47
Beta1.48
Cambio en 1 mes-3.75%
Variación en 3 meses0.62%
Cambio de 1 año-64.31%
Variación en 3 años-99.80%
Variación en 5 añosn/a
Variación desde la OPV-99.62%

Noticias y actualizaciones recientes

Recent updates

Seeking Alpha • Aug 30

Eargo: Straining To Be Heard

Summary Today, we take our first look at a small medical device company called Eargo, Inc. whose stock has slumped 90% over the past year. A good portion of the decline was caused by two key issues, both of which company management is hoping to put in the rearview mirror. An investment analysis follows in the paragraphs below. The art of conversation is the art of hearing as well as of being heard."― William Hazlitt Today, we put Eargo, Inc.(EAR) in the spotlight for the first time. This company has a variety of issues recently that have caused the stock to nosedive deep into 'Busted IPO' territory. Are brighter times on the horizon? An analysis follows below. Seeking Alpha Company Overview: Eargo, Inc. is a small medical device maker headquartered in San Jose, CA. The company markets and sells hearing aids through direct-to-consumer and through omni-channels. The stock currently has an approximate market capitalization of $75 million. The company launched the latest version of its hearing aid line, the Eargo 6 in January of this year. The Eargo 6 is an FDA Class II exempt hearing device featuring Sound Adjust technology that automatically optimizes the soundscape as the user moves between environments. June Company Presentation The company has been dogged by two major issues since it went public. The first was a criminal investigation initiated by the U.S. Department of Justice related to insurance reimbursement claims submitted by the company on behalf of its customers covered by the Federal Employee Health Benefits (FEHB) program. Management denied wrongdoing but settled this issue for $34.4 million in the Spring of this year. June Company Presentation Eargo also no longer accepted insurance as a method of direct payment in late 2021. In the second quarter of this year, Eargo operated on a cash-pay only basis which tanked sales (see section below). The company did get some very good news on this front two weeks ago as the FDA disclosed it would allow the sale of some hearing aids over the counter beginning in October. June Company Presentation The company has shipped over 110,000 hearing aid devices in its history and believes the market is significantly underpenetrated especially for its in-ear devices that offer several advantages to traditional hearing aids. June Company Presentation Second Quarter Results: On August 8th, the company posted second quarter numbers. The company had a GAAP loss of 78 cents a share as revenues plunged nearly 70% on a year-over-year basis to $7.25 million. Both top and bottom lines missed expectations badly. Returns rose to a third of sales from just less than a quarter in the same period a year ago. GAAP gross margin was 34.7%, compared to 71.8% in 2Q2021. Management stated via its earnings press release, the company would be focused on four key areas going forward. Eargo's omni-channel growth strategy Potentially regaining insurance coverage of Eargo for government employees under the FEHB program Refining and expanding the company's physical retail strategy Optimize the cash-pay business while continuing to invest in innovation. June Company Presentation Analyst Commentary & Balance Sheet: Wells Fargo ($10 price target), JPMorgan ($11 price target) and William Blair either maintained or downgraded Eargo to a Hold in the fourth quarter of 2021, but no analyst firms I can find have issued any ratings on Eargo so far in 2022. Just over one out of every ten shares are currently held short. Two insiders sold just over $40,000 in aggregate earlier this month. Another insider sold less than $15,000 worth of equity in March. That has been the only insider activity in Eargo's shares so far in 2022. The company ended the second quarter of the year with just over $106 million in cash and marketable securities on its balance sheet. This is almost entirely due to an issuance of $100 million senior secured convertible notes that occurred late in June. This is the core tranche of a $125 million strategic investment from Patient Square Capital. $16.2 million of these proceeds were used to pay off a previous debt obligation. Management will seek stockholder approval to increase the number of authorized shares and issue full potential amount of note conversion shares at its annual meeting in October of this year. If approved, this will consist of new shares of common stock created by a rights offering.
Seeking Alpha • Aug 16

Eargo jumps 77% following FDA rule on OTC hearing aids

Microcap Eargo (NASDAQ:EAR) closed up 77% on Tuesday following the U.S. FDA's announcement that it would allow the sale of some hearing aids over the counter beginning in October. Average daily volume for the company is ~4.2M shares. ~31.8M shares traded hands on Tuesday. Seeking Alpha's Quant Rating views Eargo (EAR) as a strong sell.
Seeking Alpha • Aug 08

Eargo Non-GAAP EPS of -$0.78 misses by $0.55, revenue of $7.25M misses by $21.05M

Eargo press release (NASDAQ:EAR): Q2 Non-GAAP EPS of -$0.78 misses by $0.55. Revenue of $7.25M (-68.3% Y/Y) misses by $21.05M.
Seeking Alpha • Jul 05

Eargo completes $100M senior secured convertible notes issuance

Medical device company Eargo (NASDAQ:EAR) completed the issuance of $100M senior secured convertible notes to Patient Square Capital on Jun. 28. ~$16.3M of the net proceeds was used to repay all existing third-party indebtedness and related pay-off expenses. The remaining proceeds are intended to be used for working capital purposes and to fund general business requirements. Source: Press Release
Seeking Alpha • Dec 30

Eargo: A Binary Play On Hearing Loss

Eargo has exhibited stupendous sales growth in recent years and that looks set to continue. But this growth comes at the cost of significant cash outflows that have largely increased over time. The company's value is implied to be very small at this time, which could lead to significant upside if things go right. But significant risks definitely exist, making the company a binary prospect currently.
Seeking Alpha • Oct 08

Eargo Is A High Risk 'Option' With High Potential

Eargo Inc. is a US-based small-cap public company that manufactures and distributes Completely-In-Canal (CIC) hearing aids throughout the country. The company will be one of the beneficiaries of promoting sales of OTC hearing aids in the United States. Eargo Inc. has created a highly competitive product that meets high-quality standards at an affordable price.
Artículo de análisis • Jul 10

An Intrinsic Calculation For Eargo, Inc. (NASDAQ:EAR) Suggests It's 23% Undervalued

In this article we are going to estimate the intrinsic value of Eargo, Inc. ( NASDAQ:EAR ) by estimating the company's...
Artículo de análisis • Jan 16

What Kind Of Investors Own Most Of Eargo, Inc. (NASDAQ:EAR)?

If you want to know who really controls Eargo, Inc. ( NASDAQ:EAR ), then you'll have to look at the makeup of its share...

Rentabilidad de los accionistas

EARUS Medical EquipmentMercado US
7D-2.7%4.0%-0.3%
1Y-64.3%-18.6%26.7%

Rentabilidad vs. Industria: Los resultados de EAR fueron inferiores a los de la industria US Medical Equipment, que obtuvo un rendimiento del -18.6% el año pasado.

Rentabilidad vs. Mercado: EAR obtuvo unos resultados inferiores a los del mercado US, que fueron del 26.7% el año pasado.

Volatilidad de los precios

Is EAR's price volatile compared to industry and market?
EAR volatility
EAR Average Weekly Movement2.7%
Medical Equipment Industry Average Movement8.6%
Market Average Movement7.2%
10% most volatile stocks in US Market16.2%
10% least volatile stocks in US Market3.2%

Precio estable de las acciones: EAR no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado US.

Volatilidad a lo largo del tiempo: La volatilidad semanal de EAR ha disminuido de 11% a 3% en el último año.

Acerca de la empresa

FundadaEmpleadosCEOPágina web
2010243Bill Brownieeargo.com

Eargo, Inc, empresa de dispositivos médicos, se dedica a mejorar la calidad de vida de las personas con pérdida de audición en Estados Unidos. Comercializa y vende audífonos. La empresa vende sus productos directamente al consumidor y a través de omnicanales.

Resumen de fundamentos de Eargo, Inc.

¿Cómo se comparan los beneficios e ingresos de Eargo con su capitalización de mercado?
Estadísticas fundamentales de EAR
Capitalización bursátilUS$53.39m
Beneficios(TTM)-US$108.17m
Ingresos (TTM)US$41.11m
1.3x
Ratio precio-ventas (PS)
-0.5x
Ratio precio-beneficio (PE)

¿Está EAR sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de EAR
IngresosUS$41.11m
Coste de los ingresosUS$23.86m
Beneficio brutoUS$17.25m
Otros gastosUS$125.42m
Beneficios-US$108.17m

Últimos beneficios comunicados

Sep 30, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)-5.21
Margen bruto41.95%
Margen de beneficio neto-263.14%
Ratio deuda/patrimonio0%

¿Cómo se ha desempeñado EAR a largo plazo?

Ver rendimiento histórico y comparativa

Análisis de la empresa y estado de los datos financieros

DatosÚltima actualización (huso horario UTC)
Análisis de la empresa2024/02/20 12:46
Precio de las acciones al final del día2024/02/20 00:00
Beneficios2023/09/30
Ingresos anuales2022/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

PaqueteDatosMarco temporalEjemplo Fuente EE.UU. *
Finanzas de la empresa10 años
  • Cuenta de resultados
  • Estado de tesorería
  • Balance
Estimaciones del consenso de analistas+3 años
  • Previsiones financieras
  • Objetivos de precios de los analistas
Precios de mercado30 años
  • Precios de las acciones
  • Dividendos, escisiones y acciones
Propiedad10 años
  • Accionistas principales
  • Información privilegiada
Gestión10 años
  • Equipo directivo
  • Consejo de Administración
Principales avances10 años
  • Anuncios de empresas

* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Eargo, Inc. está cubierta por 4 analistas. de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

AnalistaInstitución
Robert HopkinsBofA Global Research
Robert MarcusJ.P. Morgan
Lawrence BiegelsenWells Fargo Securities, LLC